ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform :: ProMIS Neurosciences, Inc. (PMN)

Second Quarter 2026 Earnings Conference Call Click Here

Johanne Kaplan, PhD, Chief Development Officer

Read the release here.